Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial

Multicenter Study

Comparative Study

Clinical Trial, Phase III

Meta-Analysis

Observational Study

Publication Year

From

Quick links

Individual year

2022

2021

2019

2017

2014

2012

2010

2009

2008

2007

2006

2005

2004

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Biphasic Insulins""[mesh_terms]

17 Results

Searching titles within these results

Real-Time Flash Glucose Monitoring Had Better Effects on Daily Glycemic Control Compared With Retrospective Flash Glucose Monitoring in Patients With Type 2 Diabetes on Premix Insulin Therapy.

Reng-Na Yan, Ting-Ting Cai, Lan-Lan Jiang, Ting Jing, Ling Cai, Xiao-Jing Xie, Xiao-Fei Su, Lan Xu, Ke He, Liang Cheng, Cheng Cheng, Bing-Li Liu, Yun Hu, Jian-Hua Ma

Frontiers in endocrinology 2022;13():832102

Free Full Text

Abstract

Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.

D Khutsoane, S K Sharma, M Almustafa, H C Jang, S T Azar, R Danciulescu, M Shestakova, N M A Ayad, S Guler, O M Bech

Diabetes, obesity & metabolism 2008;10(3):212-22

Full Text

Abstract

Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.

P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, S Shah, M Shestakova, Y Wenying

International journal of clinical practice 2009;63(3):522-31

Full Text

Abstract

Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.

Paul Valensi, Joseph Shaban, Marian Benroubi, Ryuzo Kawamori, Vito Borzì, Siddharth Shah, Yang Wenying, Vinay Prusty, Jes B Hansen, Janusz Gumprecht

Current medical research and opinion 2014;29(6):601-9

Full Text

Abstract

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

Rory J McCrimmon, Saud Al Sifri, Rifat Emral, Viswanathan Mohan, Leobardo Sauque-Reyna, Carlos Trescolí, Nebojsa Lalic, Agustina Alvarez, Nacima Demil, Mathieu Coudert, Alka Shaunik, Mireille Bonnemaire, Julio Rosenstock

Diabetes, obesity & metabolism 2021;23(6):1221-1231

Full Text

Abstract

The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.

P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, S Shah, M Shestakova, Y Wenying

International journal of clinical practice 2009;62(11):1809-19

Full Text

Abstract

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Jaime A Davidson, Andreas Liebl, Jens S Christiansen, Greg Fulcher, Robert J Ligthelm, Paul Brown, Titus Gylvin, Ryuzo Kawamori

Clinical therapeutics 2009;31(8):1641-51

Full Text

Abstract

Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.

Koichi Hirao, Hajime Maeda, Shinichi Urata, Yukiko Takisawa, Setsuko Hirao, Tatsuya Sasako, Tomio Sasaki

Clinical therapeutics 2007;29(5):927-934

Full Text

Abstract

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

C Ionescu Tîrgovişte, Rodica Străchinariu, Eugenia Farcaşiu, Z Milicevic, Gabriela Teodorescu

Romanian journal of internal medicine = Revue roumaine de medecine interne 2004;41(2):153-62

Full Text

Abstract

Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.

I Schmoelzer, A de Campo, H Pressl, H Stelzl, P Dittrich, K Oettl, T C Wascher

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2005;113(3):176-81

Full Text

Abstract

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

Koichi Hirao, Keiko Arai, Mikio Yamauchi, Hirofumi Takagi, Masashi Kobayashi

Diabetes research and clinical practice 2008;79(1):171-6

Full Text

Abstract

The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.

Eduard Galic, Matjaz Vrtovec, Velimir Bozikov, Maria Schwarzenhofer, Zvonko Milicevic

Medical science monitor : international medical journal of experimental and clinical research 2006;11(12):PI87-92

Full Text

Abstract

Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.

Mohammad Imtiaz Hassan, Azizul Hasan Aamir, Zahid Miyan, Laiq Ahmed Siddiqui, Muhammad Saleem Qureshi, Muhammad Zaman Shaikh

JPMA. The Journal of the Pakistan Medical Association 2012;62(9):929-36

Full Text

Abstract

Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.

Ke Su, Chunmei Lv, Zongwen Ji, Yishu Wang, Haifeng Wang, Ying Bai, Yaping Liu

American journal of therapeutics 2019;25(6):e609-e616

Full Text

Abstract

Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.

C Coscelli, G Iacobellis, C Calderini, R Carleo, M Gobbo, U Di Mario, F Leonetti, A Galluzzo, V Pirrone, M Lunetta, P Casale, F Paleari, C Falcelli, D Valle, A Camporeale, D Merante

Acta diabetologica 2004;40(4):187-92

Full Text

Abstract

Results: 1 – 15 / 17

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Biphasic Insulins""[mesh_terms]

Real-Time Flash Glucose Monitoring Had Better Effects on Daily Glycemic Control Compared With Retrospective Flash Glucose Monitoring in Patients With Type 2 Diabetes on Premix Insulin Therapy.

Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.

Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.

Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.

Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.

The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.

Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.

Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.

Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.

Biphasic insulin aspart compared to biphasic human insulin reduces postprandial hyperlipidemia in patients with Type 2 diabetes.

Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).

The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.

Safety and effectiveness of biphasic insulin aspart 30 (Biasp 30) in people with type 2 diabetes mellitus in the pakistani population: results from the A1chieve study.

Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.

Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits.

Results for
""Biphasic Insulins""[mesh_terms]